| __timestamp | Rhythm Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 1213000 | 91733000 |
| Thursday, January 1, 2015 | 3425000 | 87644000 |
| Friday, January 1, 2016 | 6311000 | 92365000 |
| Sunday, January 1, 2017 | 9518000 | 85656000 |
| Monday, January 1, 2018 | 28080000 | 88196000 |
| Tuesday, January 1, 2019 | 36550000 | 89971000 |
| Wednesday, January 1, 2020 | 46125000 | 93413000 |
| Friday, January 1, 2021 | 68486000 | 91355000 |
| Saturday, January 1, 2022 | 92032000 | 113676000 |
| Sunday, January 1, 2023 | 117532000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, Rhythm Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. have shown contrasting trends in their SG&A expenses. Rhythm Pharmaceuticals saw a staggering increase of over 9,600% in SG&A expenses, starting from a modest $1.2 million in 2014 to a peak of $117.5 million in 2023. This reflects their aggressive expansion and investment in growth. Meanwhile, Taro Pharmaceutical Industries maintained a more stable trajectory, with expenses fluctuating around the $90 million mark until 2022, before a significant jump to $198.4 million in 2023. This sudden rise could indicate strategic shifts or increased operational costs. Notably, data for Rhythm Pharmaceuticals in 2024 is missing, leaving room for speculation on their future financial strategies.
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.